Evidence blocks for effective presentation of genomic findings at molecular tumor boards: Single institution experience
Alexandra Lebedeva,
Olesya Kuznetsova,
Maxim Ivanov,
Alexandra Kavun,
Egor Veselovsky,
Ekaterina Belova,
Vladislav Mileyko,
Valentina Yakushina,
Polina Shilo,
Alexey Tryakin,
Alexey Rumyantsev,
Fedor Moiseenko,
Mikhail Fedyanin,
Dmitry Nosov
Affiliations
Alexandra Lebedeva
OncoAtlas LLC, 119049, Moscow, Russian Federation; Sechenov First Moscow State Medical University, 119049, Moscow, Russian Federation; Corresponding author. 4/1A Leninskiy Ave., Moscow, 119049, Russian Federation.
Olesya Kuznetsova
N.N. Blokhin Russian Cancer Research Center, 119049, Moscow, Russian Federation; OncoAtlas LLC, 119049, Moscow, Russian Federation
Maxim Ivanov
OncoAtlas LLC, 119049, Moscow, Russian Federation; Sechenov First Moscow State Medical University, 119049, Moscow, Russian Federation; Moscow Institute of Physics and Technology, 141701, Dolgoprudny, Moscow Region, Russian Federation
Alexandra Kavun
OncoAtlas LLC, 119049, Moscow, Russian Federation
Egor Veselovsky
OncoAtlas LLC, 119049, Moscow, Russian Federation; Department of Evolutionary Genetics of Development, Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, 119334, Moscow, Russian Federation
Ekaterina Belova
OncoAtlas LLC, 119049, Moscow, Russian Federation; Sechenov First Moscow State Medical University, 119049, Moscow, Russian Federation; Lomonosov Moscow State University, 119991, Moscow, Russian Federation
Vladislav Mileyko
OncoAtlas LLC, 119049, Moscow, Russian Federation; Sechenov First Moscow State Medical University, 119049, Moscow, Russian Federation
Valentina Yakushina
OncoAtlas LLC, 119049, Moscow, Russian Federation; Laboratory of Epigenetics, Research Centre for Medical Genetics, 115522, Moscow, Russian Federation
Polina Shilo
Lahta Clinic Medical Center, 197183, St.Petersburg, Russian Federation
Alexey Tryakin
N.N. Blokhin Russian Cancer Research Center, 119049, Moscow, Russian Federation
Alexey Rumyantsev
N.N. Blokhin Russian Cancer Research Center, 119049, Moscow, Russian Federation
Fedor Moiseenko
State Budgetary Healthcare Institution «Saint-Petersburg Clinical Scientific and Practical Center for Specialised Types of Medical Care (oncological)», 197758, Saint-Petersburg, Russian Federation
Mikhail Fedyanin
N.N. Blokhin Russian Cancer Research Center, 119049, Moscow, Russian Federation; State Budgetary Institution of Healthcare of the City of Moscow “Moscow Multidisciplinary Clinical Center “Kommunarka” of the Department of Health of the City of Moscow, 142770, Kommunarka, Moscow, Russian Federation; Federal State Budgetary Institution “National Medical and Surgical Center Named after N.I. Pirogov” of the Ministry of Health of the Russian Federation, 105203, Moscow, Russian Federation
Dmitry Nosov
The Central Clinical Hospital of the Administrative Directorate of the President of the Russian Federation, 121359, Moscow, Russian Federation
Genomic profiling, or molecular profiling of the tumor, is becoming a key component of therapeutic decision making in clinical oncology, and is typically carried out via next generation sequencing. However, the interpretation of the results and evaluation of rationale for targeting the uncovered alterations is challenging and requires a deep understanding of cancer biology, genetics, genomics and oncology. Multidisciplinary molecular tumor boards represent a promising strategy in the facilitation of molecularly-informed therapeutic decisions, and usually consist of specialists with various fields of expertise. To effectively communicate the biological and clinical significance of genomic findings, as well as to make molecular tumor board discussions more productive, we developed and implemented evidence blocks into case discussions in our center. We found that this approach facilitated clinicians’ understanding of the results of genomic profiling, and resulted in shorter yet more efficient case discussions within the molecular tumor board. Here, we discuss our experience with evidence blocks and how their implementation influenced the molecular tumor board practice.